Should You Buy Amphastar Pharmaceuticals, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Amphastar Pharmaceuticals, Inc. (AMPH) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 9.4/10. At a current price of $23.64 and a market capitalization of $1.0B, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.
The short answer: 10 of 12 CirclFi valuation models project upside for Amphastar Pharmaceuticals, Inc. (AMPH) at $23.64 — the model consensus leans bullish, with a Quality Score of 9.4/10 and Value-Trap risk of 8/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Amphastar Pharmaceuticals, Inc. (AMPH) in 2026?
What Is the Bull Case vs the Bear Case for Amphastar Pharmaceuticals, Inc. (AMPH)?
| Bull case — $84.71 target (+258.3%) | Bear case — $13.83 target (-41.5%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Amphastar Pharmaceuticals, Inc.'s rating of 9.4/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $13.83 (-41.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, 9 of 12 models identify upside from $23.64 to a median fair value of $36.21, indicating the market hasn't fully priced in Amphastar Pharmaceuticals, Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +299.8% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $84.71 (+258.3%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Amphastar Pharmaceuticals, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
| Industry tailwind: orphan drug designation could provide meaningful support for Amphastar Pharmaceuticals, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. |
How Does AMPH Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: UTHR · ZTS · AKAN · LNTH · SXTC · NBIX · IRWD · VTRS · PLNH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like AMPH on Quality?
Closest companies to AMPH’s Quality of Company score of 9.4/10, across all industries.
- PEGA — Pegasystems Inc. (QOC 9.4) · analysis
- RMBS — Rambus Inc. (QOC 9.4) · analysis
- CLS — Celestica Inc. (QOC 9.4) · analysis
- CF — CF Industries Holdings, Inc. (QOC 9.4) · analysis
- CRDO — Credo Technology Group Holding Ltd (QOC 9.4) · analysis
- ISRG — Intuitive Surgical, Inc. (QOC 9.4) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does AMPH Appear In?
So Is Amphastar Pharmaceuticals, Inc. (AMPH) Worth Buying in 2026?
The convergence of 9.4/10 quality, multi-model undervaluation (9/12 bullish, +53.2% median upside), and a median fair value of $36.21 vs. $23.64 current price makes Amphastar Pharmaceuticals, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Amphastar Pharmaceuticals, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About AMPH Stock?
Should I buy AMPH stock right now?
Based on CirclFi's multi-model analysis, 10 of 12 models see upside for AMPH at $23.64. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 9.4/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Amphastar Pharmaceuticals, Inc.?
Key risks include: wide model disagreement (513% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does AMPH compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, AMPH holds a Quality Score of 9.4/10. Comparable companies include UTHR (QOC 9.6), ZTS (QOC 9.3), AKAN (QOC 1.4). The relative ranking helps investors identify whether AMPH offers better fundamental quality than alternatives in the same sector.
Is AMPH a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. AMPH's Quality Score of 9.4/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy AMPH at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $13.83 to $84.71. At $23.64, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for AMPH.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad